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ABSTRACT
Targeting reprogrammed energy metabolism such as aerobic glycolysis is 
a potential strategy for cancer treatment. However, tumors exhibiting low-rate 
glycolysis or metabolic heterogeneity might be resistant to such treatment. We 
hypothesized that a therapeutic modality that drove cancer cells to high-rate 
glycolysis might sensitize cancer cells to interference directed against metabolic 
flux. In this study, we found that attenuated oncolytic measles virus Edmonston 
strain (MV-Edm) caused glioblastoma cells to shift to high-rate aerobic glycolysis; this 
adaptation was blocked by dichloroacetate (DCA), an inhibitor of glycolysis, leading 
to profound cell death of cancer cells but not of normal cells. DCA enhanced viral 
replication by mitigating mitochondrial antiviral signaling protein (MAVS)-mediated 
innate immune responses. In a subcutaneous glioblastoma (GBM) xenograft mouse 
model, low-dose MV-Edm and DCA significantly inhibited tumor growth in vivo. We 
found that DCA impaired glycolysis (blocking bioenergetic generation) and enhanced 
viral replication (increasing bioenergetic consumption), which, in combination, 
accelerated bioenergetic exhaustion leading to necrotic cell death. Taken together, 
oncolytic MV-Edm sensitized cancer cells to DCA, and in parallel, DCA promoted viral 
replication, thus, improving oncolysis. This novel therapeutic approach should be 
readily incorporated into clinical trials.
INTRODUCTION
Metabolic reprogramming has emerged as a key 
hallmark of cancer [1]. To provide sufficient bioenergetic 
and biosynthetic intermediates to support rapid cell 
growth and proliferation, cancer cells alter their metabolic 
flux distinct from the surrounding tissue. A well-known 
phenomenon observed in most cancer cells is a shift, 
regardless of oxygen supply, to aerobic glycolysis, 
termed “Warburg effect”, in which pyruvate is directly 
converted to lactic acid instead of entering the citric acid 
(TCA) cycle [2, 3]. Efforts have been made to target 
reprogrammed metabolism alone or in combination with 
cancer chemotherapy both in preclinical and clinical 
studies [3].
The orphan drug dichloroacetate (DCA) is 
a pyruvate mimetic. DCA has been used to treat 
human hereditary mitochondrial metabolic diseases 
and lactic acidosis for more than 30 years [4, 5]. It 
specifically inhibits the kinase family member pyruvate 
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dehydrogenase kinase (PDK) leading to reactivation of 
pyruvate dehydrogenase (PDH), a key enzyme that shifts 
the flux of pyruvate into mitochondria to promote glucose 
oxidation instead of glycolysis [6]. DCA has been recently 
evaluated in several pre-clinical cancer therapies including 
prostate [7], endometrial [8], colon [9, 10], breast 
cancer [11], lung cancer [12], and in a clinical study for 
glioblastoma [13]. In the latter study, DCA was shown to 
depolarize mitochondria, increase mitochondrial reactive 
oxygen species, and induce apoptosis in glioblastoma 
(GBM) cells, as well as in putative GBM stem cells. A 
recent study shows that the antitumor activity of DCA 
is correlated with glycolytic bias [14]. It is speculated 
that DCA holds promise against most cancers with high 
glycolysis-dependency. 
However, cancer cells within the same tumor are 
intrinsically heterogeneous due to variable blood supply, 
oxygenation status, tissue pH, etc [15]. Metabolic bias has 
also been identified in glioblastoma [16-18]. Metabolic 
heterogeneity within a tumor mass, i.e., cells exhibiting 
differential glycolysis-dependency, may contribute to 
variable responses to therapies directed against glycolysis. 
For instance, glioma cells with a glycolysis-dependent 
phenotype displayed low tolerance to glucose starvation, 
whereas glioma cells with an oxidative phosphorylation-
dependent phenotype exhibited prolonged survival under 
glucose starvation [17]. 
Viral replication is dependent on the host cellular 
metabolism for biomaterials and bioenergetics. As well, 
viral infection alters cellular metabolism to facilitate viral 
reproduction [19, 20]. An increased rate of glycolysis has 
been observed in cells following infection by any number 
of viruses including influenza virus [21], feline leukemia 
virus [22], Rous sarcoma virus [23], Avian Sarcoma 
Viruses [24], Rubella-virus [25], cytomegalovirus [26, 
27], Mayaro virus [28], Newcastle disease virus [29], 
and poliomyelitis virus [30]. This raises the possibility 
that oncolytic viruses could be employed to propel or 
synchronize cellular metabolism of cancer cells to high-
rate glycolysis.
Replicating oncolytic viruses are emerging as 
a promising modality for the treatment of malignant 
gliomas and other malignancies. Attenuated measles 
virus Edmonston strain (MV-Edm) has exhibited 
potent oncolytic activity in some preclinical studies 
against human lymphoma [31], multiple myeloma [32], 
ovarian cancer [33, 34], malignant glioma [35, 36], and 
fibrosarcoma [37]. Due to its oncolytic efficacy and 
excellent safety record, this oncolytic measles virus 
has been evaluated for treatment of cutaneous T-cell 
lymphoma [38], and is now being tested in several phase 
I/II clinical studies [39]. 
The role of MV-Edm in altering host metabolism 
is unclear. Given that cancers with high dependency on 
glycolysis are more sensitive to DCA, we hypothesized 
that a therapeutic modality employing an oncolytic virus 
to drive cancer cells to a high glycolysis-dependent 
phenotype might sensitize the tumor to DCA. In this 
study, we have investigated the metabolic adaptation of 
GBM cells to MV-Edm infection and the consequence 
of subsequent DCA treatment in vitro and in a mouse 
xenograft GBM tumor model. We found an improved 
antitumor effect at a relatively low infectious dose of virus 
in combination with DCA. 
RESULTS
MV-Edm infection shifts cellular metabolism to 
a high-rate glycolytic adaptation in glioma cells
As little is known about the metabolic alterations 
to MV-Edm infection in cancer cells, we first determined 
the glycolytic adaptation to viral infection in glioma cell 
lines U251 and U87. We found that glucose uptake in 
MV-Edm infected cells was rapidly upregulated (6 h post-
infection), and increased 15% to 20% (18 h post-infection) 
compared to uninfected GBM cells (Figure 1A). The 
increased glucose uptake following MV-Edm infection 
could be contributed by either increased aerobic glycolysis 
or glucose oxidation by TCA cycles in mitochondria. To 
discriminate between these possibilities, we monitored the 
generation of lactate, a product normally generated from 
pyruvate under hypoxic conditions, but when it occurs 
under normoxic conditions is known as aerobic glycolysis. 
We found that lactate release was rapidly increased in 
cancer cells even at 6 h after MV-Edm infection under 
normoxia (Figure 1B). Consistently, the expression of 
LDHA mRNA, which encodes a key enzyme that converts 
pyruvate to lactate, was significantly upregulated in MV-
Edm infected GBM cells (Figure 1C). Correspondingly, 
ATP generation in MV-Edm infected cells was transiently 
increased at early time points, e.g., 6 h post-infection 
(Figure 1D), indicating that cells entered into high-rate 
energy generation. Together, these results suggest that 
MV-Edm infection shifted cellular metabolism to high-rate 
aerobic glycolysis. 
DCA blocks glycolytic adaptation to MV-Edm in 
GBM cells
Previous studies have confirmed that DCA inhibits 
the conversion of pyruvate to lactate. We wanted to 
determine if DCA blocked MV-Edm induced high-
rate aerobic glycolysis. We first confirmed that DCA 
efficiently inhibited aerobic glycolysis in GBM cells, 
which was evidenced by decreased glucose uptake 
(Figure 2A), reduced lactate production (Figure 2B), and 
reduced ATP generation (Figure 2C) under normoxia. We 
further found that glucose uptake (Figure 2D) and lactate 
production (Figure 2E) and ATP generation (Figure 2F) 
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Figure 2: DCA blocks MV-Edm-induced glycolysis. (A) Glucose content was determined in the supernatant harvested from 
U251 and U87 GBM cells treated with DCA (5 mM) for 0, 3 and 6 h. Glucose uptake was reported as the percent reduction in glucose 
concentration at each time point compared to the initial (0 h) glucose level. (B & C) U251 and U87 cells were treated with or without DCA 
(5 mM) for 12 h; then (B) supernatant was tested for lactate production and (C) cell lysates were tested for ATP generation. (D - F) U251 and 
U87 cells were treated for 6 h with DCA (5 mM), MV-Edm (MOI = 0.2), MV-Edm combined with DCA, or left untreated; supernatant was 
then tested for (D) glucose uptake and (E) lactate release; cell lysates was detected for (F) ATP content. Means + SD of triplicate cultures 
are shown. Similar results were obtained in three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 1: MV-Edm shifts cellular metabolism to a high-rate glycolytic adaptation. (A) U251 and U87 GBM cells were infected 
with or without MV-Edm (MOI = 0.2) as indicated. Supernatant was harvested at 0, 3, 6, and 18 h after infection, and glucose concentration 
was determined. Glucose uptake was determined as the percent reduction in glucose concentration at each time point compared to initial 
(0 h) glucose concentration in the medium. (B) U251 and U87 cells were infected with MV-Edm at an MOI of 0.2 or 0.5, or left untreated. 
Supernatant was harvested 6 h later, and lactate release was determined. (C) LDHA expression was quantified by qRT-PCR using mRNA 
harvested from U251 and U87 cells infected with or without MV-Edm (MOI = 0.2) for 6 h. (D) ATP content was determined in cell lysates 
from U251 and U87 cells infected for 6 h with MV-Edm at a MOI of 0, 0.2, or 0.5. Data are Mean + SD of triplicates. Similar results were 
obtained in three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, # p > 0.05.
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were significantly decreased in MV-Edm/DCA treated 
cells compared to MV-Edm infection alone. These results 
show that DCA efficiently blocked glycolytic adaptation 
to MV-Edm infection in GBM cells. 
DCA promotes MV-Edm replication by impairing 
MAVS-mediated anti-viral innate immune 
responses 
Effective viral replication within cancer cells is 
crucial for oncolysis. Having shown that DCA blocked 
glycolytic adaptation to MV-Edm infection, we wondered 
if this effect compromised viral replication. To our 
surprise, in the presence of DCA viral replication was 
increased 3 to 4 fold in U251 cells, as determined by 
expression of viral structural H- and N-protein genes 24 
h post-infection (Figure 3A left panel). Consistently, we 
found that the viral particles in the supernatant were also 
increased (Figure 3A right panel). As type-I interferons 
play key roles in controlling viral replication, we evaluated 
the expression of IFNB1/IFN-β and CXCL10/IP-10, an 
interferon inducible protein. We found that mRNA levels 
of both IFNB1 and CXCL10 were significantly decreased 
in MV-Edm/DCA treated GBM cells (Figure 3B). We 
further confirmed that the decrease in IFNB1 mRNA 
expression correlated with decreased protein levels as 
determined by ELISA. IFN-β production was decreased 
in a dose-dependent manner after MV-Edm infection 
of DCA treated cells (Figure 3C). Moreover, we found 
that mitochondrial antiviral signaling protein (MAVS), 
a key adaptor protein in signaling during the anti-viral 
innate immune response, and its downstream target, 
phosphorylated IRF3, were dramatically decreased in 
GBM cells treated with MV-Edm/DCA (Figure 3D). We 
next evaluated viral replication in a GBM xenograft tumor 
Figure 3: DCA promotes viral replication by disrupting MAVS-mediated anti-viral immune responses. (A) U251 cells 
were infected with MV-Edm (MOI = 0.2) in the presence or absence of DCA (5 mM) for 24 h, then the total RNA in cells was harvested for 
the determination of viral genes encoding H and N proteins by qRT-PCR (left panel), or the supernatant was harvested for determination of 
TCID
50
 on Vero cells (right panel). Similar results were obtained in two independent experiments. (B) U251 cells were infected with MV-
Edm (MOI = 0.2) in the presence or absence of DCA (5 mM) for 24 h, then the expression of IFNB1 and CXCL10 mRNA was determined 
by qRT-PCR. Means + SD of triplicates are shown. Similar results were obtained in three independent experiments. (C) U251 cells were 
infected with MV-Edm (MOI = 0.2) in the absence or presence of DCA (5, 10, or 20 mM) for 12 h, and supernatants were then harvested, 
and the protein level of IFN-β was measured by ELISA. (D) U251 cells were treated with DCA (5 mM), MV-Edm (MOI = 0.2), MV-Edm 
combined with DCA, or left untreated, and cultured for 24 h. Cell lysates were then harvested for immunoblotting against MAVS or pIRF3; 
β-actin was used as a loading control. A representative result from two independent experiments is shown. (E) U87 cells were inoculated 
subcutaneously into Balb/c nude mice. When tumors reached a palpable size, one group of mice received DCA (70 mg/L) in the drinking 
water for 10 d (n = 6). Another group was left untreated (n = 7). Then both groups of mice were injected with MV-Edm-Luc (4 x 105 pfu per 
mouse) via tail vein. Luciferase activity was monitored by an in vivo luminescence imaging system 72 h after virus injection (left panel). 
Photons per cm2 tumor were quantified (right panel). * p < 0.05, ** p < 0.01, *** p < 0.001.
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model. Viral replication was monitored by in vivo imaging 
following intravenous injection of a genetically modified 
MV-Edm expressing a luciferase gene (MV-Edm-Luc) in 
U87 glioma-bearing mice. The mean luciferase activity 
in tumors, reflecting viral replication, was higher in mice 
treated with MV-Edm/DCA than in mice treated with 
MV-Edm alone (Figure 3E). Although the difference did 
not reach statistical significance between the two groups 
(p = 0.051), a trend of improved viral replication in vivo 
was evident. Taken together, the data suggest that DCA 
promotes MV-Edm replication by disrupting MAVS-
mediated anti-viral immune responses.
Combining DCA with low-dose MV-Edm 
enhances antitumor efficacy in GBM
Having shown that DCA blocks aerobic glycolytic 
adaptation to MV-Edm, and that DCA promotes viral 
replication, we next investigated the antitumor activity 
of MV-Edm/DCA in GBM. In vitro, enhanced antitumor 
effects were achieved by combining low-dose MV-Edm 
(MOI = 0.2) with DCA at a concentration of 5 mM (Figure 
4A). Importantly, we found that MV-Edm/DCA treatment 
had only minimal effects on the viability of the normal 
human endothelial cell line ECV304 (Figure 4B). Next, 
we wanted to know if low-dose MV-Edm combined 
with DCA could contribute to an improved therapeutic 
outcome in vivo. We established a GBM xenograft model 
by subcutaneous inoculation of U87 cells into Balb/c 
nude mice. First, we confirmed that MV-Edm infection 
produced a significant inhibition of tumor growth (Figure 
4C). Then, employing a lower infectious dose of MV-Edm 
(total dose, 3.2 × 106 PFU per mouse) we found that DCA 
combined with low-dose MV-Edm significantly inhibited 
tumor growth, whereas only marginal tumor inhibition was 
observed in mice receiving either DCA or low-dose MV-
Edm single treatment (Figure 4D). The dosage of DCA 
Figure 4: DCA combined with low-dose MV-Edm exerts an enhanced anti-tumor effect. (A) U251 and U87 glioma cells or 
(B) ECV304 human endothelial cells were infected or uninfected with MV-Edm (MOI = 0.2) followed by addition of DCA at a concentration 
of 5 mM for 48 or 72 h. Untreated cells were used as negative controls. Cell viability was determined by trypan blue exclusion. Means ± 
SD of triplicates are shown. Similar results were obtained in three independent experiments. (C) Male Balb/c nude mice (6 to 8 week old) 
were injected subcutaneously with U87 cells in the left flank on day 0 and randomized to two groups (n = 8 per group). Tumors became 
palpable on day 5. Starting on day 10 after tumor inoculation, one group of mice received MV-Edm (8 x 105 PFU per mouse) via tail vein 
injection every other day from day 10 to 18 and from day 25 to 39 (total dose of 1 x 107 PFU MV-Edm). (D) Male Balb/c nude mice (6 to 8 
week old) were injected subcutaneously with U87 cells in the left flank on day 0 and randomized to four groups as depicted. The treatment 
groups received DCA supplemented in drinking water (70 mg/L) on day 6 (n = 6), or received low-dose MV-Edm (4 x 105 PFU per mouse) 
injection via tail vein every 3 days from day 15 to 27 and from day 36 to 42 (n = 6) (total dose of 3.2 × 106 PFU), or received both DCA and 
MV-Edm administration (n = 6). An untreated group (n = 5) was used as a control. Data are mean ± SD. * p < 0.05, ** p < 0.01, *** p < 
0.001, # p > 0.05. (E) Body weight of mice was monitored during the treatment. Means ± SD of each group at various time points are shown. 
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was similar to previous studies [6, 12] and to that used 
clinically [13]. No significant side-effect was observed 
as evidenced by the comparable body weight among four 
groups (Figure 4E). These data show that DCA with low-
dose MV-Edm improves therapeutic outcome. 
Accelerated exhaustion of bioenergetics leads to 
necrosis in GBM cells
Finally, we sought to clarify the mechanism 
underlying enhanced antitumor activity of MV-Edm/DCA. 
Since apoptosis has been suggested as the mechanism of 
cell death induced by DCA or MV-Edm in glioma [13, 
37], we investigated the contribution of apoptosis to 
the combined antitumor effect. We found that z-VAD-
fmk, a pan caspase inhibitor, failed to inhibit MV-Edm/
DCA induced cell death (Figure 5A). Given that DCA 
blocked glycolytic adaptation to MV-Edm (impairment 
of rapid energy generation) and that DCA promoted 
viral replication (promotion of energy consumption), 
we speculated that MV-Edm/DCA treatment might 
accelerate bioenergetic exhaustion. Having shown that 
ATP generation was transiently increased due to high-rate 
glycolytic adaptation upon MV-Edm infection (Figure 
1D), we assessed cellular ATP levels at later timepoints. 
We found that ATP levels were significantly decreased 
along with viral replication 36 and 48 h after MV-Edm 
infection (Figure 5B). We found that ATP levels were 
dramatically decreased in MV-Edm/DCA treated GBM 
cells compared to cells with single treatment (Figure 
5C). An energy crisis in cells treated with MV-Edm/
DCA was further indicated by a massive increase in the 
level of pAMPK (Figure 5C), an energy sensor triggered 
by insufficient ATP supply. These data suggest that 
an accelerated bioenergetic shortage may dominantly 
contribute to the enhanced antitumor effect. In view 
Figure 5: Necrosis contributes to MV-Edm/DCA mediated oncolysis by accelerated bioenergetics exhaustion. (A) U251 
and U87 cells were treated with DCA (5 mM), MV-Edm (MOI = 0.2), MV-Edm combined with DCA in the presence or absence of z-VAD-
fmk (80 μM), or left untreated. Cell viability was determined by trypan blue exclusion 60 h post-treatment. Similar results were obtained in 
two independent experiments. (B) ATP content was determined in cell lysates harvested from U251 and U87 cells infected with MV-Edm 
at an MOI of 0.2 for 24, 36, or 48 h. Untreated cells were used as a negative control. Means + SD of triplicates are shown. Similar results 
were obtained in three independent experiments. (C) U251 and U87 cells were treated with DCA (5 mM), MV-Edm (MOI = 0.2), MV-Edm 
combined with DCA, or left untreated for 48 h. Cell lysates were then harvested for determination of ATP content (upper panel), or for 
immunoblotting against AMPK and phosphorylated AMPK (lower panel). Similar results were obtained in three independent experiments. 
(D) U251 and U87 cells were treated with MV-Edm (MOI = 0.2), DCA (5 mM), MV-Edm combined with DCA, or left untreated for 48 h. 
Cell lysates (C) and supernatants (S) were harvested for immunoblotting against HMGB1. β-actin was used as a loading control. Similar 
results were obtained in three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, # p > 0.05. 
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of the fact that a cellular ATP shortage mainly leads to 
necrosis, and the fact that the high mobility group box1 
(HMGB1) has been identified as a danger signal released 
from necrotic cells that can be used as a necrotic marker 
[40], we evaluated the HMGB1 level in the cytoplasm and 
supernatant of MV-Edm/DCA treated cells. We found that 
the HMGB1 level was increased in the supernatant and in 
parallel was decreased in the cytoplasm of MV-Edm/DCA 
treated GBM cells (Figure 5D), which confirmed necrotic 
cell death. These data imply that MV-Edm/DCA induces a 
severe bioenergetic crisis in GBM cells leading to necrotic 
cell death.
DISCUSSION
We hypothesized that an intervention modality that 
initially drove cancer cells to high glycolysis-dependency 
followed by a treatment directed against glycolysis might 
improve the antitumor effect. In this study, we found that 
the self-replicating MV-Edm shifts cellular metabolism to 
a high-rate glycolytic adaptation, which can be efficiently 
targeted by DCA, leading to improved antitumor activity 
both in vitro and in a tumor-bearing mouse model. We 
did not observe any toxicity. Our data indicated that 
DCA promoted MV-Edm replication by impairing the 
MAVS-mediated anti-viral innate immune response. The 
therapeutic approach of combining DCA with low-dose 
MV-Edm produced an enhanced antitumor effect that 
resulted in dominant necrotic cell death due to a severe 
shortage of cellular ATP in GBM cells. Given that both 
MV-Edm and DCA have been effectively tested in clinical 
studies, this novel strategy could be readily moved from 
bench to bedside. 
MV-Edm infection upregulates glycolysis under 
aerobic conditions (the Warburg effect) in glioblastoma 
cells, which was evidenced by increased glucose uptake, 
lactate production, and LDHA expression upon MV-
Edm infection. We observed a rapid increase in ATP 
generation suggesting that cancer cells were shifted to a 
high-rate glycolytic adaptation. Similar to other viruses 
that upregulate glycolysis [33-42], the metabolic shift 
toward glycolysis presumably favors both viral replication 
and host cell survival. It is thought that viruses mobilize 
glycolysis of infected cells to provide sufficient nutrients 
and energy for viral replication, and infected cells shift 
to high-rate glycolysis for rapid generation of ATP to 
compensate for the “robbed bioenergetics”.
We found that DCA significantly improved 
oncolysis of low-dose MV-Edm both in vitro and in vivo. 
The improved antitumor effect was achieved through two 
distinct effects. First, DCA successfully blocked glycolytic 
adaptation to MV-Edm infection. Given that the antitumor 
activity of DCA is likely to be enhanced in cancer cells 
with more glycolysis-dependency [14], the conversion to 
high-rate glycolysis mediated by MV-Edm infection would 
make GBM cells more vulnerable to DCA induced cell 
death. Second, DCA promoted viral replication in GBM, 
which would enhance its oncolytic effect. The enhanced 
viral replication in MV-Edm/DCA treated cells is likely 
the consequence of impaired innate immune responses 
mediated by MAVS, a key adaptor protein in antiviral 
signaling [41]. The MAVS protein level was markedly 
decreased in GBM cells, suggesting that MV-Edm/DCA 
treatment enhanced MAVS degradation. However, the 
precise mechanism is unknown in our setting and needs 
further study. It has been reported that mitochondrial 
membrane potential (Δψm) is required for MAVS-
mediated anti-viral signaling [42], and that DCA reduces 
Δψm via remodeling mitochondria [43]. It is possible that 
reduced Δψm (data not shown) might partially contribute 
to impaired MAVS signaling. The enhanced viral 
replication induced by DCA makes this strategy attractive, 
as viral replication is crucial for improving MV-Edm-
mediated oncolysis. Thus, the combinational modality 
of MV-Edm/DCA represents an efficient and practical 
strategy for clinical oncolytic virotherapy.
The enhanced cell death was a result of necrosis 
rather than apoptosis. In MV-Edm/DCA treated cells, cell 
viability could not be rescued by the pan caspase inhibitor 
z-VAD-fmk. Previous studies show that ATP exhaustion 
predominantly leads to necrosis [44]. We confirmed that 
the necrosis was a consequence of a severe bioenergetics 
crisis, as MV-Edm/DCA treatment dramatically decreased 
ATP generation. Necrotic cell death was directly 
confirmed by finding increased levels of HMGB1 in the 
supernatant of MV-Edm/DCA treated cells, which was 
accompanied by a parallel decrease in HMGB1 expression 
in the cytoplasm. 
The bioenergetic exhaustion in MV-Edm/
DCA treated GBM cells was the consequence of two 
synchronous factors: enhanced bioenergetics consumption 
and impaired bioenergetics generation. On the one hand, 
despite the rapid increase in ATP generation upon MV-
Edm infection at early time points due to the cellular 
glycolytic adaptation, the ATP level was decreased along 
with viral replication 36 h post-infection due to massive 
bioenergetics consumption. Moreover, DCA promoted 
viral replication, and thus, accelerated ATP exhaustion 
in MV-Edm/DCA treated cells. On the other hand, 
DCA blocked aerobic glycolytic adaptation to MV-Edm 
infection, which further exacerbated the bioenergetics 
crisis. It is also plausible that the improved viral replication 
might facilitate viral spread to neighboring non-infected 
cells, which in turn, would sensitize more GBM cells to 
DCA mediated inhibition of glycolysis, a vicious cycle 
ultimately leading to enhanced antitumor activity.
It is important to note that no obvious side-effects 
were observed in treated mice. The safety of this strategy 
was also confirmed by our observation in vitro that 
normal human endothelial cells are resistant to MV-Edm/
DCA treatment. Possible explanations might be that MV-
Edm is non-toxic or mildly-toxic to normal cells and that 
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under normoxic conditions normal cells shunt glycolytic 
pyruvate into the TCA cycle rather than conversion to 
lactate. These advantages may provide a wide therapeutic-
window for a MV-Edm/DCA treatment modality. 
Several oncolytic viruses have been shown to 
elicit anti-tumor immune responses [38, 45-47]. As 
well, DCA is able to enhance antitumor immunity [48]. 
Thus, it would be interesting to determine whether MV-
Edm/DCA treatment elicits a more profound antitumor 
immunity. Because our in vivo study was conducted in 
immunocompromised mice bearing human GBM cells 
(as measles virus only infects primates or humans), 
immunologic reactions could not be reliably assessed. 
Further studies using immunocompetent mice, e.g., 
CD46 transgenic mice, may permit a comprehensive 
analysis. Of note, recent studies have shown that lactate 
may compromise anti-tumor immune responses [49, 50], 
and we showed that DCA significantly decreased lactate 
production in cancer cells infected with MV-Edm. Thus, 
MV-Edm/DCA modality might contribute to amplify the 
anti-tumor immune responses by reducing tumor lactate 
production, which deserves further intensive investigation. 
It has been shown recently that mTOR inhibitor rapamycin 
decreases lactate production in cancer cell lines regardless 
of normoxia or hypoxia [51, 52], which may also extend 
our further anticancer investigation to target aerobic 
glycolytic adaptation to oncolytic viruses by mTOR 
inhibitors.
In summary, our work provides a novel, clinically 
relevant, therapeutic strategy that provides a rationale for 
combining oncolytic virotherapy with a treatment modality 
targeting reprogrammed cancer cell metabolism. The 
strategy is based on two promising antitumor strategies, 
both of which have been tested in clinical studies, and 
which can be readily translated to clinical cancer therapy.
METHODS 
Cells and reagents
The human glioblastoma cell lines U251 and U87 
and human ECV304 endothelial cells and Vero cells were 
cultured in DMEM supplemented with 5% fetal bovine 
serum, 2 mM L-glutamine, 100 U/l penicillin and 0.1 
mg/ml streptomycin (all from Invitrogen, Karlsruhe, 
Germany). Cultures were maintained in a humidified 
incubator with 5% CO
2
 at 37°C. Dichloroacetate (DCA), 
Adenosine Triphosphate (ATP), and z-VAD-fmk were all 
obtained from Sigma-Aldrich (Taufkirchen, Germany). 
Glucose uptake and lactate release assay
Supernatants were harvested from cultured U251 
and U87 cells at various time points after treatment. 
To determine glucose uptake, glucose concentration 
in culture supernatants was determined using a glucose 
assay kit (Shanghai Rongsheng Biotech, Shanghai, China, 
F006) according to the manufacturer’s instructions, and 
quantified by absorption at 450 nm. Lactate generation 
was measured using a lactate assay kit according to 
the manufacturer’s instruction (Nanjing Jiancheng 
Bioengineering Institute, Nanjing, China, A019-2). Briefly, 
NAD+ is added to the media and is converted to NADH 
stoichiometrically by lactate in the medium. The levels of 
NADH were quantified colorimetrically at 530 nm.
ATP detection
Intracellular ATP was measured by a luciferin-
luciferase method using with an ATP assay kit (Beyotime 
Inst. Biotech, Jiangsu, China, S0026). In brief, cells were 
washed once with PBS and transferred to lysis buffer. The 
supernatants were harvested by centrifugation at 12000 g 
for 10 min at 4°C, and mixed with ATP detection buffer 
and analyzed by luminescence spectrometry. The final 
ATP content of each sample was normalized to protein 
concentration measured by BCA Protein Assay Kit 
(Beyotime Inst. Biotech, Jiangsu, China, P0012).
Virus titration
MV-Edm and MV-Edm expressing a reporter gene 
luciferase (MV-Edm-luc, kindly provided by S. Russell, 
Mayo Clinic, MN, USA) were propagated in Vero cells 
following infection at an MOI of 0.02 in 2 ml OptiMEM 
(Invitrogen, 31985-062) at 37°C for 3 h. The medium was 
changed to DMEM supplemented with 2% FCS and cells 
were incubated at 37°C for 1 day before being transferred 
to 32°C for another day. Cells were harvested, and viral 
particles were released by two cycles of snap freezing 
in liquid nitrogen and thawing in 37°C water bath. Or 
the supernatant from glioma cells infected with MV-
Edm in the presence or absence of DCA were harvested, 
centrifuged, and stored at -80°C until used. Viral titers 
were determined by 50% end-point dilution assays 
(TCID
50
) on Vero cells. 
Cell viability assay 
Cells were harvested using trypsin/EDTA solution 
and stained with trypan blue. Viability was then 
determined by trypan blue exclusion using a Countstar 
Automated cell counter (Inno-Alliance Biotech Inc., 
Wilmington, USA). 
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ELISA
Supernatants from treated or untreated cells 
were harvested, centrifuged, and stored at -80°C until 
used. Samples were analyzed using an ELISA assay for 
detection of IFNB1/IFN-ß (R&D Systems, Minneapolis, 
MN, 41410-1A) according to the manufacturer’s protocol.
Quantitative RT-PCR
For quantitative RT-PCR (qPCR), 
total cellular RNA was extracted with TRIZOL 
(Invitrogen, 15596-026) and 1 µg of RNA was reverse-
transcribed using the Master Mix Perfect Real Time kit 
(TaKaRa, Shiga, Japan, DRR036A) according to the 
manufacturer’s protocol. qPCR was performed using the 
Real-Time PCR system (ABI 7300, Advanced Biosystems, 
Foster, CA). Gene expression was calculated with the 
comparative Ct method and normalized to the endogenous 
levels of GAPDH. Primer sequences used for qPCR were: 
CXCL10, 5’-CTTCCAAGGATGGACCACACA-3’ 
and 5’-CCTTCCTACAGGAGTAGTAGCAG-3’; 
IFNB1, 5’-CTTGGATTCCTACAAAGAAGC-3’ 
and 5’-CATCTCATAGATGGTCAATGC-3’; 
MV-Edm N-protein, 5’-ACATTAGCATC 
TGAACTCGGTATCAC-3’ and 
5’-TTTTCGCTTTGATCACCGTGTA-3’; MV-Edm 
H-protein, 5’-GATGACAAGTTGCGAATGGAGA-3’ 
and 5’-GACAAGACCCCGTATGAAGGAA-3’; 
LDHA, 5’-GCCCGACGTGCATTCCCGATTCCTT-3’ 
and 5’-GACGGCTTTCTCCCTCTTGCTGACG-3’; 
GAPDH, 5’-CCACCCATGGCAAATTCCAT -3’ and 5’- 
TCTAGACGGCAGGTCAGGTCC-3’. 
Western blot
Cells were lysed in RIPA buffer containing a 
protease inhibitor cocktail (Roche, Mannheim, Germany, 
11873580001). Protein concentration was determined. 
Equal amounts of protein were separated by SDS-
PAGE and electrophoretically transferred onto a PVDF 
membrane (Roche, 03010040001). After blocking 
with 5% nonfat milk in Tris-buffered saline containing 
0.1% Tween-20, the membrane was incubated with 
specific primary antibodies, followed by incubation 
with appropriate horseradish peroxidase–conjugated 
secondary antibodies. Signals were developed using 
an enhanced chemiluminescence reagent (Millipore, 
Darmstadt, Germany, WBKLS0500) and captured on 
an Alpha Innotech Fluor Chem FC2 imaging system 
(Alpha Innotech, San Leanardo, CA). Antibodies used 
in this study were: rabbit anti-β-ACTIN (Biosynthesis 
Biotechnology, Beijing, China, bs0061R, 1:1000), rabbit 
anti-HMGB1 (Abcam, Hong Kong, China, ab191583, 
1:1000), rabbit anti-AMPK/pAMPK (Cell Signaling 
Technology, Danvers, MA, #2532 / #2531, 1:1000), rabbit 
anti MAVS (Abcam, ab31334, 1:500) and HRP-conjugated 
secondary antibodies (Multisciences, Hangzhou, China, 
GAR007 and GAM007, 1:5000).
Visualization of MV-Edm replication in vivo
Male Balb/c nude mice (6-8 week old) were 
injected subcutaneously with 1×106 U87 cells in the left 
flanks and randomized to 2 groups. When tumors reached 
palpable size, one group of mice was treated for 10 days 
with DCA (70 mg/L in drinking water). Both groups of 
mice then received 4 × 105 PFU MV-Edm-Luc via tail 
vein injection. Three days after MV-Edm injection, mice 
were anesthetized and injected intraperitoneally with 
D-luciferin (Gold Biotechnology, St. Louis, MO) and 
subjected to luciferase assay using the IVIS Lumina XR 
system (Caliper Life Sciences, Hopkinton, MA). The 
level of firefly luciferase was expressed as the ROI value 
normalized to tumor volume. 
In vivo treatment with high-dose MV-Edm
Male Balb/c nude mice (6-8 week old) were injected 
subcutaneously with 1×106 U87 cells in the left flanks on 
day 0 and randomized to 2 groups (n = 8 per group). Mice 
received 8×105 PFU MV-Edm via tail vein injection every 
other day from day 10 to 18 and day 25 to 39. Total dose of 
MV-Edm for each mouse was 1×107 PFU. Untreated mice 
were used as negative controls. Tumors were measured 
every 3 days, and tumor volume was calculated as length 
x width2/2. 
In vivo treatment by combining DCA with low-
dose MV-Edm 
Male Balb/c nude mice (6-8 week old) were injected 
subcutaneously with 1×106 U87 cells in the left flanks 
on day 0 and randomized to 4 groups (5 to 6 mice per 
group). On day 6, two groups of mice were provided 
drinking water containing DCA (70 mg/L) until the end of 
the experiment. Starting 15 days after tumor inoculation, 
two groups of mice treated with DCA or untreated, were 
injected intravenously with 4×105 PFU MV-Edm every 
3 days from day 15 to 27 and day 36 to 42. Total dose 
of MV-Edm for each mouse was 3.2 x 106 PFU. Tumors 
were measured every 3 days, and tumor volume was 
calculated as length x width2/2. Mice exhibiting moribund 
behavior were euthanized. All animal work was approved 
by the Animal Care Committee of Nanjing University 
in accordance with Institutional Animal Care and Use 
Committee guidelines. 
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Statistical analyses 
Student t test was used for all in vitro statistical 
analyses. The Mann–Whitney U-test was used for two-
group luciferase activity comparison. Statistical analysis of 
tumor volume among the groups was done using repeated 
measures ANOVA. P < 0.05 was considered significant.
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